Showing 5021-5030 of 5963 results for "".
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2458016/The American Society for Dermatologic Surgery (ASDS) introduced their new Vice Presid
- Alastin Skincare Launches Trihex Transition Duo at ASDShttps://practicaldermatology.com/news/alastin-skincare-launches-trihex-transition-duo-at-asds/2458027/ALASTIN Skincare®, Inc. is launching the TriHex Transition Duo at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. The TriHex Transition Duo includes a full-size Regenerating Skin Nectar for use pre- and post-procedure and a
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://practicaldermatology.com/news/fda-clears-fontinas-starwalker-maqx-ultra-performance-q-switched-system/2458038/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo